Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia

Stephanie C. Wu, James S. Wrobel, David G. Armstrong

Research output: Contribution to journalReview article

13 Scopus citations


Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.

Original languageEnglish (US)
Pages (from-to)S33-S42
JournalPain Medicine
Issue numberSUPPL. 2
StatePublished - Sep 1 2007



  • Diabetes
  • Fibromyalgia
  • Foot
  • Neuropathy
  • Pain
  • Quality of Life
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this